{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:45:32Z","timestamp":1791179132980,"version":"4.1.0"},"reference-count":12,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2005,2,1]]},"DOI":"10.1200\/jco.2005.10.980","type":"journal-article","created":{"date-parts":[[2004,12,22]],"date-time":"2004-12-22T03:00:17Z","timestamp":1103684417000},"page":"657-658","source":"Crossref","is-referenced-by-count":17,"title":["Mantle Cell Lymphoma: At Last, Some Hope for Successful Innovative Treatment Strategies"],"prefix":"10.1200","volume":"23","author":[{"given":"Richard I.","family":"Fisher","sequence":"first","affiliation":[{"name":"James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-199207000-00001"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.11.3909"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.4.1075.bloodjournal8541075"},{"key":"R4","unstructured":"Press OW, Grogan TM, Fisher RI: Evaluation and management of mantle cell lymphoma. Adv Leuk Lymph 6:3,1996-11,"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.2.317"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.5.1288"},{"key":"R7","doi-asserted-by":"crossref","unstructured":"Hiddemann W, Dreyling M, Unterhalt M, et al: Effect of the addition of rituximab to front line therapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) on the remission rate and time to treatment failure compared to CHOP alone in mantle cell lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. Proc Am Soc Clin Oncol 23:556,2004,  (abstr 6501)","DOI":"10.1200\/jco.2004.22.90140.6501"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.12.3803"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.050"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.108"},{"key":"R11","unstructured":"Assouline S, Belch A, Sehn L, et al: A phase II study of bortezomib in patients with mantle cell lymphoma. Blood 102:902a,2003,"},{"key":"R12","unstructured":"Dunleavy KM, Janik J, Grant N, et al: Phase I\/II study of bortezomib combined with dose adjusted EPOCH chemotherapy in relapsed or refractory diffuse large B-cell lymphoma. Blood 102:636a,2003-637a,"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2005.10.980","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T20:39:34Z","timestamp":1653511174000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2005.10.980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2,1]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,2,1]]}},"alternative-id":["10.1200\/JCO.2005.10.980"],"URL":"https:\/\/doi.org\/10.1200\/jco.2005.10.980","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,2,1]]}}}